These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1071637)

  • 21. Receptor binding and biological activity of 18-oxocortisol.
    Gomez-Sanchez CE; Gomez-Sanchez EP; Smith JS; Ferris MW; Foecking MF
    Endocrinology; 1985 Jan; 116(1):6-10. PubMed ID: 2856875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid specificity of renal type I receptors: binding and metabolism of corticosterone.
    Doyle D; Smith R; Krozowski ZS; Funder JW
    J Steroid Biochem; 1989 Aug; 33(2):165-70. PubMed ID: 2549303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mineralocorticoid hormone pathways in hypertension with hyperaldosteronism.
    Biglieri EG; Kater CE; Brust N; Chang B; Hirai J
    Clin Exp Hypertens A; 1982; 4(9-10):1677-83. PubMed ID: 7139973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding characteristics of mineralocorticoid and glucocorticoid receptors in dog brain and pituitary.
    Reul JM; de Kloet ER; van Sluijs FJ; Rijnberk A; Rothuizen J
    Endocrinology; 1990 Aug; 127(2):907-15. PubMed ID: 2164924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid activity of 16beta-hydroxydehydroepiandrosterone and related steroids.
    Gomez-Sanchez C; Holland OB; Higgins JR; Mathieu R; Gruber GM; Milewich L; Kaplan NM
    J Lab Clin Med; 1976 Oct; 88(4):571-7. PubMed ID: 135037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
    Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
    Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone.
    Witzgall H; Thayil G; Weber PC
    Klin Wochenschr; 1982 Aug; 60(16):847-52. PubMed ID: 6752560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous determination of plasma 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, and aldosterone in man.
    Ojima M; Aida M; Kambegawa A
    Tohoku J Exp Med; 1978 Apr; 124(4):367-79. PubMed ID: 663934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RU-26988--a new tool for the study of the mineralocorticoid receptor.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    Endocrinology; 1983 Sep; 113(3):1004-9. PubMed ID: 6307658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid secretion in essential hypertension with normal and low plasma renin activity.
    Messerli FH; Kuchel O; Nowaczynski W; Seth K; Honda M; Kubo S; Boucher R; Tolis G; Genest J
    Circulation; 1976 Mar; 53(3):406-10. PubMed ID: 1248073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids.
    Lan NC; Graham B; Bartter FC; Baxter JD
    J Clin Endocrinol Metab; 1982 Feb; 54(2):332-42. PubMed ID: 6274900
    [No Abstract]   [Full Text] [Related]  

  • 32. The regulation of plasma 18-hydroxy 11-deoxycorticosterone in man.
    Williams GH; Braley LM; Underwood RH
    J Clin Invest; 1976 Jul; 58(1):221-9. PubMed ID: 180059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of spironolactone binding sites distinct from aldosterone receptors in rat kidney homogenates.
    Luzzani F; Glässer A
    Biochem Pharmacol; 1984 Jul; 33(14):2277-81. PubMed ID: 6235813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of aminoglutethimide on blood pressure and steroid secretion in patients with low renin essential hypertension.
    Taylor AA; Mitchell JR; Bartter FC; Snodgrass WR; McMurtry RJ; Gill JR; Franklin RB
    J Clin Invest; 1978 Jul; 62(1):162-8. PubMed ID: 149141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension and aldosterone overproduction without renin suppression in Cushing's syndrome from an adrenal adenoma.
    Guthrie GP; Kotchen TA
    Am J Med; 1979 Sep; 67(3):524-8. PubMed ID: 474601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for an antagonist specific receptor that does not bind mineralocorticoid agonists.
    Lazar G; Agarwal MK
    Biochem Biophys Res Commun; 1986 Jan; 134(1):261-5. PubMed ID: 3004430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of aldosterone receptors in rat kidney: effects of steroid treatment and potassium diet.
    Rafestin-Oblin ME; Claire M; Lombes M; Michaud A; Corvol P
    J Steroid Biochem; 1984 Oct; 21(4):465-70. PubMed ID: 6238210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The natural history of salt-wasting disorders of adrenal and renal origin.
    Rösler A
    J Clin Endocrinol Metab; 1984 Oct; 59(4):689-700. PubMed ID: 6384251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of 19-nor-deoxycorticosterone to other mineralocorticoids in low-renin hypertension.
    Griffing GT; Dale SL; Holbrook MM; Melby JC
    Hypertension; 1983; 5(3):385-9. PubMed ID: 6341221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid characteristics of mineralocorticoid adrenocortical hypertension.
    Biglieri EG; Kater CE
    Clin Chem; 1991 Oct; 37(10 Pt 2):1843-8. PubMed ID: 1914200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.